Pharma Pulse 6/13/24 : PBMs Start to Embrace Biosimilars, Novo Nordisk Threatens Lego’s Position in Denmark & more

Dynamic Pricing: What Pharma Needs?

With pharmacies under pressure to lower drug-acquisition costs, a look at how digital formats can help manufacturers better manage price based on real-time data.

PBMs Start to Embrace Biosimilars

Pharmacy benefit managers (PBMs) are slowly coming around and putting biosimilars on their formularies. IQVIA estimates that the dearth of a Humira (adalimumab) biosimilars last year cost patients and employers cumulatively $6 billion.

Establishing a Data Ecosystem Using Automation to Optimize Regulatory-Compliant Clinical Trials

Significant advances in technology are providing new opportunities to collect and utilize real-world data to establish better clinical trial protocols that have a patient-centric focus and the ability to transform healthcare. However, it is important to understand how such applications work and their impact on safety.

This webcast series uncovers the concerns of safety professionals and other stakeholders involved in the development and implementation of clinical trial protocols in the digital era and highlights methods to best apply digital data into routine practice to best optimize trial success and adhere to strict regulatory guidance.

Novo Nordisk Threatens Lego’s Position as Denmark’s No. 1 Brand

Denmark’s Lego A/S has long reigned as the country’s most valuable brand, but the toymaker is now under threat of being toppled by Novo Nordisk A/S, whose weight-loss treatments have become a global pop culture phenomenon.

IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites

IQVIA announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site needs to perform across all of the clinical trials it is conducting.

Brice Challamel on LinkedIn:

I had the privilege to be by interviewed by Pharmaceutical Executive a couple of weeks ago, and share Moderna's current philosophy regarding AI adoption and how AI is reshaping our ways of working. You can follow this link to a 5 minute video with attached transcript if you'd like to learn more.

There are a few other videos that you can browse on the site on adjacent topics such as Responsible AIs or the Challenges we had to overcome so far to meet the moment!

Special thanks to Miranda Schmalfuhs for running the interview and Kelly (Shaw) Cunningham for helping me prepare for it.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs